Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048903 | 0.77 | CYP19A1 (0.47) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL317330 | 0.76 | CYP19A1 (0.60) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL14845696 | 0.76 | LOXL2 (0.46) | HRH4MAPTPOLBCA12CA9 | |
| SCHEMBL30917347 | 0.76 | CYP19A1 (0.60) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL1673078 | 0.75 | CYP19A1 (0.76) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL28389620 | 0.74 | CYP19A1 (0.59) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL12778277 | 0.72 | CYP19A1 (0.58) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL10172985 | 0.72 | CYP19A1 (0.58) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL27277838 | 0.72 | CYP19A1 (0.58) | CYP19A1HRH4MAPTPOLBMAOB | |
| SCHEMBL1465120 | 0.72 | CYP19A1 (0.54) | CYP19A1HRH4MAPTPOLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230100634-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220411410-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-12-29 | — | — | US | disclosed |
| CN-101460489-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| EP-2007756-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmceuticals Incorporated (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411410-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885HRH4 2082/4885MAPT 4484/4885 |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885HRH4 2082/4885MAPT 4484/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | CYP19A1 3622/4885HRH4 998/4885MAPT 4528/4885 |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885HRH4 2082/4885MAPT 4484/4885 |
| US-20230100634-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885HRH4 2082/4885MAPT 4484/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885HRH4 2082/4885MAPT 4484/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | CYP19A1 2885/4885HRH4 1163/4885MAPT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.